AACR 2023 | Is adjuvant immunotherapy necessary in non-small cell lung cancer?
David Carbone, MD, PhD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, comments on the role of adjuvant immunotherapy in treating non-small cell lung cancer (NSCLC). Results from the CheckMate 816 (NCT02998528) and AEGEAN (NCT03800134) trials have demonstrated modest survival benefit in patients who receive neoadjuvant and adjuvant chemoimmunotherapy. However, since findings from the LCMC3 study (NCT02927301) of neoadjuvant atezolizumab provide similar results, further research is required to assess the role of adjuvant immunotherapy. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Well, adjuvant atezolizumab is also approved for lung cancer, when they were resected without neoadjuvant, The real question in the field right now is that it appears to me that the benefit of neoadjuvant chemoimmunotherapy is dramatic as shown in the CheckMate-816 study. What we saw in this presentation of the AACR’s AEGEAN study is that neoadjuvant chemo-IO with adjuvant IO is also a positive for event free survival...
Well, adjuvant atezolizumab is also approved for lung cancer, when they were resected without neoadjuvant, The real question in the field right now is that it appears to me that the benefit of neoadjuvant chemoimmunotherapy is dramatic as shown in the CheckMate-816 study. What we saw in this presentation of the AACR’s AEGEAN study is that neoadjuvant chemo-IO with adjuvant IO is also a positive for event free survival. But it wasn’t strikingly different than what you saw with CheckMate-816 with no adjuvant immunotherapy. So, the main question in the field really now is who needs adjuvant immunotherapy? And the LCMC3 study suggests to me that neoadjuvant immunotherapy alone, followed by adjuvant chemo and adjuvant IO, yields similar survival outcomes as you see in AEGEAN-816. If you give neoadjuvant chemo-IO like in 816 IO or AEGEAN. It’s unclear to me that AEGEAN suggests that adjuvant IO is important. It’s a whole year of therapy that’s quite expensive and the early results from AEGEAN are not much different from what you saw with CheckMate-816.
Read more...
